Aldevron Breakthrough Blog

Streamlining mRNA Production

November 8, 2023 / by Nate Spangler, Ph.D.

Seeking guidance for a big investment

Messenger RNA (mRNA) based drugs and vaccines make up a new class of medicine showing tremendous promise. Compared to established drug and vaccine technologies, mRNA has the potential to reach patients faster by being easier to develop and produce.

But that’s not to say that the production of mRNA-based medicines is simple; it involves many steps requiring a range of specialized expertise and capabilities. This is where contract development and manufacturing organizations (CDMOs) can be beneficial. Outsourcing is an effective way to access specialized capabilities, adaptable experience, and honed expertise for getting drug products to the market faster.

In an ongoing series of blog posts, we will explore key factors to consider when evaluating CDMO options, with an emphasis on streamlining and de-risking supply chains by finding a CDMO that can satisfy as many needs as possible from a single supplier. Topics we will consider include:

Much of this series will be on the last point where expertise, capabilities, reputation, and flexibility come into focus. Finding the right CDMO involves many considerations. The goal of this series of posts is to provide an overview to help those developing mRNA-based medicines choose outsourcing partners wisely.


Nate Spangler, Ph.D.

Nate Spangler, Ph.D.

Nathan Spangler is Aldevron’s Senior Director of Innovation & Strategy. Located in Madison, Nathan was instrumental in planning and building Aldevron’s recombinant antibody and protein business. For nearly two decades, he has supported discovery and development of drugs through R&D and commercialization of tools and technologies, as well as the building and management of contract development and research businesses in the life sciences industry.